\begin{table}
	\centering
	\caption{Sensitivity analyses: relative incidence in at-risk period versus control period of all outcomes for Zostavax with and without concomitant vaccines and considering all events or first events only.}
	\label{tab:ri_sens}
	\resizebox{\textwidth}{!}{%
	\begin{tabular}{lrrrr}
		\toprule
		& \begin{tabular}{@{}c@{}}Vaccines modelled jointly \\ all events \end{tabular} & 
		\begin{tabular}{@{}c@{}}Vaccines modelled independently \\ (concomitant vaccines excluded) \\ all events \end{tabular} & 
		\begin{tabular}{@{}c@{}} Vaccines modelled jointly \\ first events only \end{tabular} & 				\begin{tabular}{@{}c@{}} Vaccines modelled independently\\ (concomitant vaccines excluded)  \\ first events only \end{tabular} \\
		\midrule 
		Injection site reaction & 77.4 (48.1, 124.6) & 60.5 (37.4, 97.9) & 71.2 (43.6, 116.1) & 57.3 (34.8, 94.3) \\
		Burn & 1.23 (0.97, 1.57) & 1.12 (0.86, 1.47) & 1.08 (0.78, 1.50) & 1.12 (0.80, 1.58) \\
		Myocardial infarction & 0.74 (0.41, 1.33) & 0.70 (0.35, 1.36) & 0.90 (0.49, 1.66) & 0.80 (0.39, 1.64) \\
		Stroke &0.58 (0.44, 0.78)& 0.51 (0.37, 0.71)& 0.54 (0.37, 0.77)& 0.51 (0.34, 0.76) \\
		Any rash & 0.97 (0.88, 1.08) & 0.96 (0.86, 1.07) & 1.01 (0.90, 1.14) & 1.01 (0.89, 1.14) \\
		Rash with antiviral & 0. 83 (0.62, 1.10) & 0.67 (0.49, 0.92) & 0.80 (0.59, 1.09)& 0.64 (0.45, 0.90)\\
		Clinical attendance & 1.23 (0.97, 1.57) & 0.94 (0.93, 0.94) & NA & NA \\
		\bottomrule
	\end{tabular}}
\end{table}